Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Sol-Gel Technologies announced that the last patient has completed the final visit in their pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for preventing basal cell carcinoma in Gorlin syndrome patients. The company will now finalize data analysis and expects to report top-line results by late November 2026. This milestone advances t…